0000000000269680

AUTHOR

Alexej Ballhausen

0000-0002-5470-4973

showing 4 related works from this author

The sharedneoantigen landscape of MSI cancers reflects immunoediting during tumor evolution

2019

AbstractThe immune system can recognize and attack cancer cells, especially those with a high load of mutation-inducedneoantigens. Suchneoantigens are particularly abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and toneoantigen-inducing translational frameshifts. The abundance of mutationalneoantigens renders MSI cancers sensitive to immune checkpoint blockade. However, the neoantigen landscape of MMR-deficient cancers has not yet been systematically mapped. In the present study, we used a novel tool to monitorneoantigen-inducing indel mutations in MSI colore…

0303 health sciencesImmunogenicityfood and beveragesBiologydigestive system diseasesImmune checkpoint3. Good health03 medical and health sciences0302 clinical medicineImmune systemImmunoediting030220 oncology & carcinogenesisCancer cellCancer researchDNA mismatch repairIndelINDEL Mutation030304 developmental biology
researchProduct

Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance

2021

Regular colonoscopy even with short intervals does not prevent all colorectal cancers (CRC) in Lynch syndrome (LS). In the present study, we asked whether cancers detected under regular colonoscopy surveillance (incident cancers) are phenotypically different from cancers detected at first colonoscopy (prevalent cancers). We analyzed clinical, histological, immunological and mutational characteristics, including panel sequencing and high-throughput coding microsatellite (cMS) analysis, in 28 incident and 67 prevalent LS CRCs (n total = 95). Incident cancers presented with lower UICC and T stage compared to prevalent cancers (p &lt

OncologyColorectal cancerColonoscopybiomarkkeritHEREDITARYGUIDELINESTp53 mutationmedicine.disease_causeMolecular level0302 clinical medicineRISKincident cancercancer preventionmedicine.diagnostic_testRGeneral MedicineTUMORSLynch syndrome3. Good healthsyöpäsolutCARCINOMAS030220 oncology & carcinogenesisMedicineDNA mismatch repair030211 gastroenterology & hepatologyKRAScarcinogenesiskoloskopiamedicine.medical_specialtyDATABASEcolorectal cancersuolistosyövätmikrosatelliititArticle03 medical and health sciencescolonoscopy screeningInternal medicinemutational profilingmedicineLynchin oireyhtymäPathologicalpaksusuolisyöpäCancer preventionmismatch repair deficiencybusiness.industryMicrosatellite instabilitySCREENING INTERVAL3126 Surgery anesthesiology intensive care radiologymedicine.diseasedigestive system diseasesMSH2Lynch syndromeMSH23121 General medicine internal medicine and other clinical medicineT-stageCLINICAL MANAGEMENTmicrosatellite instabilitymutaatiotbusinessJournal of Clinical Medicine
researchProduct

The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution

2020

The immune system can recognize and attack cancer cells, especially those with a high load of mutation-induced neoantigens. Such neoantigens are abundant in DNA mismatch repair (MMR)-deficient, microsatellite-unstable (MSI) cancers. MMR deficiency leads to insertion/deletion (indel) mutations at coding microsatellites (cMS) and to neoantigen-inducing translational frameshifts. Here, we develop a tool to quantify frameshift mutations in MSI colorectal and endometrial cancer. Our results show that frameshift mutation frequency is negatively correlated to the predicted immunogenicity of the resulting peptides, suggesting counterselection of cell clones with highly immunogenic frameshift peptid…

0301 basic medicineMutation rateGeneral Physics and Astronomymedicine.disease_causeCOLORECTAL-CANCER0302 clinical medicineINDEL MutationMutation RateimmunologiaHLA AntigensNeoplasmsFrameshift Mutationlcsh:ScienceImmunologic SurveillanceGeneticsMutationMultidisciplinaryMISMATCH REPAIR DEFICIENCYQPEPTIDES3. Good healthkohdunrungon syöpäsyöpäsolutimmuunivaste030220 oncology & carcinogenesisTumour immunologyMicrosatellite InstabilityDNA mismatch repairINDEL MutationEXPRESSIONcongenital hereditary and neonatal diseases and abnormalitieskasvaimetDATABASESciencegastrointestinal cancerINSTABILITY3122 CancerssuolistosyövätBiologycomplex mixturesArticleGeneral Biochemistry Genetics and Molecular BiologyFrameshift mutationGastrointestinal cancer03 medical and health sciencesAntigens NeoplasmCOLONmedicineHumansCELLSelection GeneticIndelSIGNATUREStumour immunologyMicrosatellite instabilityGeneral ChemistryDNAmedicine.disease3126 Surgery anesthesiology intensive care radiologydigestive system diseases030104 developmental biologyImmunoeditinglcsh:Qmutaatiotbeta 2-MicroglobulinMicrosatellite Repeats
researchProduct

Abstract 571: The shared mutation and neoantigen landscape of MMR-deficient colorectal cancers suggests immunoediting during tumor evolution

2019

Abstract The immune system can recognize and attack cancer cells and their precursors, especially those with a high load of mutation-induced neoantigens. Such neoantigens are particularly abundant in DNA mismatch repair (MMR)-deficient cancers. MMR deficiency results in microsatellite instability (MSI), which leads to multiple insertion/deletion mutations at coding microsatellites and to neoantigen-inducing translational frameshifts. The significance of immune selection and immunoediting potentially shaping the neoantigen landscape during the progression from premalignant MMR-deficient lesions into cancers has not yet been analyzed. We hypothesized that the neoantigen landscape of MSI cance…

Genetics0303 health sciencesCancer ResearchMutationCancerMicrosatellite instabilityHuman leukocyte antigenBiologymedicine.diseasemedicine.disease_cause3. Good healthFrameshift mutation03 medical and health sciences0302 clinical medicineOncologyImmunoeditingmedicineDNA mismatch repairMutation frequency030304 developmental biology030215 immunologyCancer Research
researchProduct